.png){kind=icon}
.png){kind=icon}
Return
NCCN Continuing Education
.png){kind=icon}
OA
AI
DOI：10.6004/jnccn.2024.0014.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Mesothelioma is a rare cancer that originates from the mesothelial surfaces of the pleura and other sites, and is estimated to occur in approximately 3,500 people in the United States annually. Pleural mesothelioma is the most common type and represents approximately 85% of these cases. The NCCN Guidelines for Mesothelioma: Pleural provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with pleural mesothelioma. These NCCN Guidelines Insights highlight signi ficant updates to the NCCN Guidelines for Mesothelioma: Pleural, including revised guidance on disease classi fication and systemic therapy options.
Keywords:
MALIGNANT-PLEURAL-MESOTHELIOMA
PEMETREXED PLUS CISPLATIN
MULTICENTER PHASE-II
HYPERTHERMIC INTRATHORACIC CHEMOTHERAPY
LONG-TERM SURVIVAL
CELL LUNG-CANCER
EXTRAPLEURAL PNEUMONECTOMY
UNITED-STATES
PHOTODYNAMIC THERAPY
TRIMODALITY THERAPY
Journal
J
IF:
16.4
Papers:
2.8K
Citations:
1.5W
Organization
View more organizations